FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379015109> ?p ?o ?g. }

• W4379015109 endingPage "61" @default.
• W4379015109 startingPage "54" @default.
• W4379015109 abstract "Anticoagulant therapy might reduce the number of miscarriages and adverse pregnancy outcomes in women with recurrent pregnancy loss and inherited thrombophilia. We aimed to assess use of low-molecular-weight heparin (LMWH) versus standard care in this population.The ALIFE2 trial was an international open-label, randomised controlled trial undertaken in hospitals in the UK (n=26), the Netherlands (n=10), the USA (n=2), Belgium (n=1), and Slovenia (n=1). Women aged 18-42 years who had two or more pregnancy losses and confirmed inherited thrombophilia, and who were trying to conceive or were already pregnant (≤7 weeks' gestation), were eligible for inclusion. Women were randomly assigned (1:1) to use low-dose LMWH or not (alongside standard care in both groups) once they had a positive urine pregnancy test. LMWH was started at or before 7 weeks' gestation and continued until the end of pregnancy. The primary outcome measure was livebirth rate, assessed in all women with available data. Safety outcomes included bleeding episodes, thrombocytopenia, and skin reactions, and were assessed in all randomly assigned women who reported a safety event. The trial was registered within the Dutch Trial Register (NTR3361) and EudraCT (UK: 2015-002357-35).Between Aug 1, 2012, and Jan 30, 2021, 10 625 women were assessed for eligibility, 428 were registered, and 326 conceived and were randomly assigned (164 to LMWH and 162 to standard care). 116 (72%) of 162 women with primary outcome data in the LMWH group and 112 (71%) of 158 in the standard care group had livebirths (adjusted odds ratio 1·08, 95% CI 0·65 to 1·78; absolute risk difference, 0·7%, 95% CI -9·2% to 10·6%). 39 (24%) of 164 women in the LMWH group and 37 (23%) of 162 women in the standard care group reported adverse events.LMWH did not result in higher livebirth rates in women who had two or more pregnancy losses and confirmed inherited thrombophilia. We do not advise use of LMWH in women with recurrent pregnancy loss and inherited thrombophilia, and we advise against screening for inherited thrombophilia in women with recurrent pregnancy loss.National Institute for Health and Care Research and the Netherlands Organization for Health Research and Development." @default.
• W4379015109 created "2023-06-02" @default.
• W4379015109 creator A5000735539 @default.
• W4379015109 creator A5024423524 @default.
• W4379015109 creator A5028355102 @default.
• W4379015109 creator A5029077697 @default.
• W4379015109 creator A5039192427 @default.
• W4379015109 creator A5046488569 @default.
• W4379015109 creator A5062058100 @default.
• W4379015109 creator A5062657695 @default.
• W4379015109 creator A5066626384 @default.
• W4379015109 creator A5075271442 @default.
• W4379015109 creator A5087495070 @default.
• W4379015109 creator A5091704063 @default.
• W4379015109 date "2023-07-01" @default.
• W4379015109 modified "2023-10-10" @default.
• W4379015109 title "Heparin for women with recurrent miscarriage and inherited thrombophilia (ALIFE2): an international open-label, randomised controlled trial" @default.
• W4379015109 cites W1938739174 @default.
• W4379015109 cites W1963736844 @default.
• W4379015109 cites W2048626087 @default.
• W4379015109 cites W2105361494 @default.
• W4379015109 cites W2107453274 @default.
• W4379015109 cites W2161580096 @default.
• W4379015109 cites W2170707517 @default.
• W4379015109 cites W2292858884 @default.
• W4379015109 cites W2747087713 @default.
• W4379015109 cites W2925290838 @default.
• W4379015109 cites W3008221221 @default.
• W4379015109 cites W3010676413 @default.
• W4379015109 cites W3119101527 @default.
• W4379015109 cites W3126421251 @default.
• W4379015109 cites W3158644112 @default.
• W4379015109 cites W3159531122 @default.
• W4379015109 cites W3175353778 @default.
• W4379015109 cites W4229066215 @default.
• W4379015109 cites W4231905096 @default.
• W4379015109 cites W4238278966 @default.
• W4379015109 cites W4285098083 @default.
• W4379015109 doi "https://doi.org/10.1016/s0140-6736(23)00693-1" @default.
• W4379015109 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37271152" @default.
• W4379015109 hasPublicationYear "2023" @default.
• W4379015109 type Work @default.
• W4379015109 citedByCount "4" @default.
• W4379015109 countsByYear W43790151092023 @default.
• W4379015109 crossrefType "journal-article" @default.
• W4379015109 hasAuthorship W4379015109A5000735539 @default.
• W4379015109 hasAuthorship W4379015109A5024423524 @default.
• W4379015109 hasAuthorship W4379015109A5028355102 @default.
• W4379015109 hasAuthorship W4379015109A5029077697 @default.
• W4379015109 hasAuthorship W4379015109A5039192427 @default.
• W4379015109 hasAuthorship W4379015109A5046488569 @default.
• W4379015109 hasAuthorship W4379015109A5062058100 @default.
• W4379015109 hasAuthorship W4379015109A5062657695 @default.
• W4379015109 hasAuthorship W4379015109A5066626384 @default.
• W4379015109 hasAuthorship W4379015109A5075271442 @default.
• W4379015109 hasAuthorship W4379015109A5087495070 @default.
• W4379015109 hasAuthorship W4379015109A5091704063 @default.
• W4379015109 hasConcept C126322002 @default.
• W4379015109 hasConcept C131872663 @default.
• W4379015109 hasConcept C141071460 @default.
• W4379015109 hasConcept C168563851 @default.
• W4379015109 hasConcept C187212893 @default.
• W4379015109 hasConcept C197934379 @default.
• W4379015109 hasConcept C2776884760 @default.
• W4379015109 hasConcept C2777557582 @default.
• W4379015109 hasConcept C2779234561 @default.
• W4379015109 hasConcept C2779245376 @default.
• W4379015109 hasConcept C2780625311 @default.
• W4379015109 hasConcept C2780842393 @default.
• W4379015109 hasConcept C2780868729 @default.
• W4379015109 hasConcept C2908647359 @default.
• W4379015109 hasConcept C29456083 @default.
• W4379015109 hasConcept C46973012 @default.
• W4379015109 hasConcept C54355233 @default.
• W4379015109 hasConcept C71924100 @default.
• W4379015109 hasConcept C86803240 @default.
• W4379015109 hasConcept C99454951 @default.
• W4379015109 hasConceptScore W4379015109C126322002 @default.
• W4379015109 hasConceptScore W4379015109C131872663 @default.
• W4379015109 hasConceptScore W4379015109C141071460 @default.
• W4379015109 hasConceptScore W4379015109C168563851 @default.
• W4379015109 hasConceptScore W4379015109C187212893 @default.
• W4379015109 hasConceptScore W4379015109C197934379 @default.
• W4379015109 hasConceptScore W4379015109C2776884760 @default.
• W4379015109 hasConceptScore W4379015109C2777557582 @default.
• W4379015109 hasConceptScore W4379015109C2779234561 @default.
• W4379015109 hasConceptScore W4379015109C2779245376 @default.
• W4379015109 hasConceptScore W4379015109C2780625311 @default.
• W4379015109 hasConceptScore W4379015109C2780842393 @default.
• W4379015109 hasConceptScore W4379015109C2780868729 @default.
• W4379015109 hasConceptScore W4379015109C2908647359 @default.
• W4379015109 hasConceptScore W4379015109C29456083 @default.
• W4379015109 hasConceptScore W4379015109C46973012 @default.
• W4379015109 hasConceptScore W4379015109C54355233 @default.
• W4379015109 hasConceptScore W4379015109C71924100 @default.
• W4379015109 hasConceptScore W4379015109C86803240 @default.
• W4379015109 hasConceptScore W4379015109C99454951 @default.
• W4379015109 hasIssue "10395" @default.

• next